STCube, Inc. (KOSDAQ: 052020)

Market Cap	376.64B
Revenue (ttm)	9.94B
Net Income (ttm)	-23.76B
Shares Out	49.43M
EPS (ttm)	-509.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	465,665
Open	7,530.00
Previous Close	7,750.00
Day's Range	7,280.00 - 7,790.00
52-Week Range	3,940.00 - 12,700.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 21, 2025

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi...

• Industry: Electronic Parts and Equipment, not elsewhere classified
• Founded: 1989
• Employees: 17
• Stock Exchange: KOSDAQ
• Ticker Symbol: 052020

Financial Performance

In 2023, STCube's revenue was 5.83 billion, a decrease of -7.54% compared to the previous year's 6.30 billion. Losses were -24.34 billion, 28.7% more than in 2022.